Optimal Timing of Zoster Vaccination After Shingles: A Prospective Study of the Immunogenicity and Safety of Live Zoster Vaccine / 감염과화학요법
Infection and Chemotherapy
; : 311-318, 2018.
Article
de En
| WPRIM
| ID: wpr-722315
Bibliothèque responsable:
WPRO
ABSTRACT
BACKGROUND: Zoster vaccination is recommended for people with a history of herpes zoster (HZ), but the most effective timing of vaccine administration after zoster illness is unresolved. This prospective observational study compared the immunogenicity and safety of administering HZ vaccine at 6-12 months and 1-5 years after zoster illness. MATERIALS AND METHODS: Blood samples were collected before the administration of live zoster vaccine and 6 weeks after vaccination. Varicella-zoster virus (VZV) IgG concentrations and T-cell responses were assessed by glycoprotein enzyme-linked immunosorbent assay and interferon-γ enzyme-linked immunospot assay (ELISPOT), respectively. RESULTS: The baseline geometric mean value (GMV) of VZV IgG was higher in the 6-12 months group than in the 1-5 years group (245.5 IU/mL vs. 125.9 IU/mL; P = 0.021). However, the GMV increased significantly in both groups (P = 0.002 in the 6-12 months group; P 1 year after zoster illness. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02704572
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Immunoglobuline G
/
Test ELISA
/
Glycoprotéines
/
Lymphocytes T
/
Études prospectives
/
Vaccination
/
Herpèsvirus humain de type 3
/
Vaccin contre le zona
/
Test ELISpot
/
Étude d'observation
Type d'étude:
Observational_studies
/
Prognostic_studies
langue:
En
Texte intégral:
Infection and Chemotherapy
Année:
2018
Type:
Article